Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Anne Tourette"'
Autor:
Emilie Decaup, Cédric Rossi, Pauline Gravelle, Camille Laurent, Julie Bordenave, Marie Tosolini, Anne Tourette, Emeline Perrial, Charles Dumontet, Mary Poupot, Christian Klein, Ariel Savina, Jean-Jacques Fournié, Christine Bezombes
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Follicular lymphoma (FL) is the second most frequent subtype of B non-Hodgkin's lymphomas (NHL) for which the treatment is based on the use of anti-CD20 mAbs. NK cells play a crucial role in their mechanism of action and the number of these cells med
Externí odkaz:
https://doaj.org/article/edac4580725a42f69c8ffc364c78d22b
Autor:
Chloé Grasselly, Morgane Denis, Aurore Bourguignon, Nolan Talhi, Doriane Mathe, Anne Tourette, Laurent Serre, Lars Petter Jordheim, Eva Laure Matera, Charles Dumontet
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
In spite of impressive response rates in multiple cancer types, immune checkpoint inhibitors (ICIs) are active in only a minority of patients. Alternative strategies currently aim to combine immunotherapies with conventional agents such as cytotoxic
Externí odkaz:
https://doaj.org/article/bf272d7ef5c84fddaf27c5badc894146
Autor:
Charles Dumontet, Eva-Laure Matera, Christian Klein, Lars Petter Jordheim, Elsa Kress, Fabian Birzele, Aurore Bourguignon, Nolan Talhi, Anne Tourette, Kamel Chettab, Doriane Mathé, Anne Wierinckx, Pierre-Antoine Choffour, Chloé Grasselly, Morgane Denis
Supplementary Data from In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti–PD-1/PD-L1 Therapies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c1d470b26a064a247545c2063ac39c1
https://doi.org/10.1158/2326-6066.22545206.v1
https://doi.org/10.1158/2326-6066.22545206.v1
Autor:
Charles Dumontet, Eva-Laure Matera, Christian Klein, Lars Petter Jordheim, Elsa Kress, Fabian Birzele, Aurore Bourguignon, Nolan Talhi, Anne Tourette, Kamel Chettab, Doriane Mathé, Anne Wierinckx, Pierre-Antoine Choffour, Chloé Grasselly, Morgane Denis
Antibodies targeting PD-1 and PD-L1 have produced durable responses in a subset of patients with cancer. However, a majority of these patients will ultimately relapse due to acquired resistance. To explore the underlying mechanisms of this secondary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94f888b755b1943311e115d6c0ed7178
https://doi.org/10.1158/2326-6066.c.6550883.v1
https://doi.org/10.1158/2326-6066.c.6550883.v1
Autor:
Morgane Denis, Chloé Grasselly, Pierre-Antoine Choffour, Anne Wierinckx, Doriane Mathé, Kamel Chettab, Anne Tourette, Nolan Talhi, Fabian Birzele, Elsa Kress, Lars Petter Jordheim, Christian Klein, Eva-Laure Matera, Charles Dumontet
Publikováno v:
Cancer Research. 82:4200-4200
The underlying mechanisms of acquired resistance to the immune checkpoint inhibitory (ICI) PD-1 and PD-L1 antibodies remain largely unknown and need to be further explored. In this study, we established and analyzed robust ICI resistance in in vivo m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c48ce0db5b23c3e7f5b0460bce21f0c5
https://doi.org/10.1158/1538-7445.am2022-4200
https://doi.org/10.1158/1538-7445.am2022-4200
Autor:
Charles Dumontet, Fabrice Gardebien, Guillaume Beck, Alessandra Nurisso, Eva-Laure Matera, Anne Tourette, Romain Haudecoeur, Doriane Mathe, Marine Peuchmaur, Grégory Bouchaud, Basile Pérès, Antoine Magnan, Ahcène Boumendjel, Guillaume Monneret, Justine Esmenjaud, Eve Mattei, Cédric Boyère
Publikováno v:
European Journal of Medicinal Chemistry
European Journal of Medicinal Chemistry, Elsevier, 2018, 158, pp.405-413. ⟨10.1016/j.ejmech.2018.09.033⟩
European Journal of Medicinal Chemistry, Elsevier, 2018, 158, pp.405-413. ⟨10.1016/j.ejmech.2018.09.033⟩
International audience; Phosphatidylinositide 3-kinases (PI3Ks) are widely expressed enzymes involved in membrane signalization pathways. Attempts to administer inhibitors with broad activity against different isoforms have failed due to toxicity. Co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ca7e0dfbd92df260affaada5241699e
https://pubmed.ncbi.nlm.nih.gov/30237123
https://pubmed.ncbi.nlm.nih.gov/30237123
Autor:
Aurore Bourguignon, Anne Tourette, Laurent Serre, Lars Petter Jordheim, Nolan Talhi, Chloé Grasselly, Charles Dumontet, Morgane Denis, Doriane Mathe
Publikováno v:
Cancer Research. 78:2723-2723
Immune checkpoint inhibitors (ICIs) show impressive response rate in multiple cancer types. Nivolumab and atezolizumab has already been approved by the FDA. However, a large proportion of patients do not show any benefits or will develop acquired res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::36b365ad400a6f4085761e790f9ace0d
https://doi.org/10.1158/1538-7445.am2018-2723
https://doi.org/10.1158/1538-7445.am2018-2723